Von Hippel Lindau Disease Clinical Trial
Official title:
Data Collection Protocol for Patients With Von Hippel Lindau Disease
To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.
| Status | Recruiting |
| Enrollment | 125 |
| Est. completion date | December 31, 2026 |
| Est. primary completion date | December 31, 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Presence of genetic confirmation or clinical criteria consistent with vHL disease. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: • Patients with psychiatric illness/social situations that would limit compliance with study requirements. |
| Country | Name | City | State |
|---|---|---|---|
| United States | M D Anderson Cancer Center | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| M.D. Anderson Cancer Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Progression-free survival (PFS) | through study completion; an average of 1 year |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
| Terminated |
NCT00001803 -
Von Hippel-Lindau Disease Genetic Epidemiology Study
|
||
| Enrolling by invitation |
NCT00102544 -
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
|
N/A | |
| Terminated |
NCT01015300 -
Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
|
Phase 0 |